The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy

Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. Methods We prospectively enrolled 60...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer medicine (Malden, MA) MA), 2020-01, Vol.9 (1), p.43-51
Hauptverfasser:	Park, Hyunkyung, Bang, Ju‐Hee, Nam, Ah‐Rong, Park, Ji Eun, Jin, Mei Hua, Bang, Yung‐Jue, Oh, Do‐Youn
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Antineoplastic Combined Chemotherapy Protocols - therapeutic use biomarker Biomarkers Biomarkers, Tumor - blood Blood Blood platelets Chemotherapy Clinical Cancer Research Diagnosis Disease Progression Female Fluorouracil - therapeutic use Growth factors Humans Irinotecan - therapeutic use Kaplan-Meier Estimate Laboratories Leucovorin - therapeutic use Lymphocytes Male Medical prognosis Metastasis Middle Aged Neutrophils Original Research Oxaliplatin - therapeutic use Palliative Care - methods Pancreatic cancer Pancreatic Neoplasms - blood Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pathogenesis Patients Prognosis Progression-Free Survival Prospective Studies Survival Transforming Growth Factor beta - blood Transforming growth factor-b transforming growth factor‐beta
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. Methods We prospectively enrolled 60 patients treated with FOLFIRINOX as the first‐line palliative chemotherapy. We collected blood samples at the time of diagnosis, first response assessment, and disease progression and measured serum sTGF‐β using an enzyme‐linked immunosorbent assay. Results The patients’ median overall survival (OS) and progression‐free survival (PFS) were 10.3 (95% confidence interval [CI], 8.5‐12.1) and 6.5 (95% CI, 4.9‐8.1) months, respectively. Patients with low sTGF‐β at diagnosis (
ISSN:	2045-7634 2045-7634
DOI:	10.1002/cam4.2677